Gallbladder Disease (Biliary Colic & Cholecystitis)

Gallbladder disease encompasses a spectrum of conditions ranging from asymptomatic gallstones (cholelithiasis) to symptomatic biliary colic, acute and chronic cholecystitis, choledocholithiasis, cholangitis, and gallstone pancreatitis. Gallstones are the most common biliary pathology and represent one of the most frequent reasons for elective and emergency surgical admission in Australia.

In Australia, gallstone disease is estimated to affect 10–15% of the adult population. The prevalence increases with age, female sex (female-to-male ratio approximately 2–3:1), obesity (BMI >30 kg/m²), rapid weight loss, pregnancy, diabetes mellitus, and certain ethnic backgrounds. Gallstone-related admissions account for over 60,000 hospital separations annually, with laparoscopic cholecystectomy being one of the most commonly performed general surgical procedures nationally.

Aboriginal and Torres Strait Islander Australians experience gallstone disease at rates 2–5 times higher than the non-Indigenous population, with earlier age of onset and higher rates of gallbladder cancer. The AIHW reports that biliary disease is among the top 10 reasons for hospitalisation in First Nations Australians, particularly in remote and very remote communities.

Biliary colic is the cardinal symptom of uncomplicated gallstone disease. The term "colic" is a misnomer — the pain is typically steady (not colicky) and results from transient cystic duct obstruction by a gallstone, producing gallbladder distension. Understanding the characteristic presentation is critical for distinguishing biliary colic from more serious complications such as acute cholecystitis, cholangitis, and gallstone pancreatitis.

Clinical Features of Biliary Colic

• Pain character: Sudden-onset, steady (not colicky), intense visceral pain in the RUQ or epigastrium; the patient is typically restless and unable to find a comfortable position.
• Timing: Often begins 30–60 minutes after a fatty meal (e.g., fried foods, full-cream dairy); may also occur nocturnally (gallbladder stasis during fasting).
• Duration: Typically 30 minutes to 4–6 hours; if pain persists beyond 6 hours, suspect acute cholecystitis or other complications.
• Radiation: Classic radiation to the right shoulder tip (via phrenic nerve irritation) or interscapular region (referred pain via T7–T10 dermatomes).
• Associated symptoms: Nausea, vomiting, bloating; no fever, no jaundice.
• Resolution: Spontaneous resolution as the stone disimpacts from the cystic duct; between attacks the patient is entirely well with a normal examination.
• Examination between attacks: Normal — no RUQ tenderness, no Murphy's sign, no fever, no jaundice.

Differential Diagnosis

Natural History

Approximately 70–80% of patients with a single episode of biliary colic will have recurrent symptoms. The natural history of untreated symptomatic gallstones is progression to complications: approximately 1–2% per year develop acute cholecystitis, 0.5–1% develop choledocholithiasis, and 0.1–0.5% develop gallstone pancreatitis. Early elective cholecystectomy is therefore recommended after the first or second confirmed episode of biliary colic to prevent complications and repeated emergency presentations.

The initial workup for suspected gallbladder disease is guided by the clinical presentation — asymptomatic incidental gallstones, suspected biliary colic, or possible complicated gallstone disease (cholecystitis, cholangitis, pancreatitis). The goals of investigation are to confirm gallstones, assess for complications, and exclude alternative diagnoses.

First-Line Investigations

Second-Line and Specialist Investigations

Excluding Acute Cholecystitis and Cholangitis

The following findings on initial workup should prompt consideration of complicated gallstone disease rather than simple biliary colic:

• Acute cholecystitis indicators: Pain >6 hours, fever (≥37.8°C), positive Murphy's sign on examination, gallbladder wall thickening (>3 mm) or pericholecystic fluid on ultrasound, leukocytosis (WCC >11 × 10⁹/L), elevated CRP.
• Acute cholangitis indicators: Charcot's triad (RUQ pain + fever + jaundice) — sensitivity approximately 50–70%; Reynold's pentad adds hypotension and altered mental status indicating suppurative cholangitis. Deranged LFTs with obstructive pattern (elevated ALP, GGT, conjugated bilirubin). Requires urgent blood cultures and IV antibiotics.
• Gallstone pancreatitis indicators: Severe epigastric pain radiating to the back, nausea/vomiting, lipase >3× ULN. Can be distinguished from biliary colic by the severity and location of pain, markedly elevated lipase, and the absence of spontaneous resolution within 4–6 hours.

Gallstones form when the concentration of cholesterol, bile salts, or bilirubin in bile becomes supersaturated, leading to crystal nucleation and stone growth within the gallbladder. The three main types of gallstones are:

• Cholesterol stones (80–85%): Formed from supersaturated bile with excess cholesterol relative to bile salts and lecithin. Associated with obesity, high-fat diets, female sex, pregnancy, and certain medications (e.g., oral contraceptives, fibrates).
• Pigment stones (15–20%): Composed of calcium bilirubinate. Black pigment stones are associated with haemolytic disorders (sickle cell disease, hereditary spherocytosis, thalassaemia), cirrhosis, and Gilbert syndrome. Brown pigment stones are associated with biliary infection (Clonorchis, Ascaris) and are more common in East Asian populations.
• Mixed stones: Combination of cholesterol and calcium components; most common in clinical practice.

Biliary colic occurs when a gallstone transiently impacts in the cystic duct, causing gallbladder wall distension and visceral pain mediated by C-fibre afferents. The stone typically disimpacts spontaneously (within hours) as gallbladder contraction ceases, allowing the stone to fall back into the gallbladder lumen or pass into the CBD.

Acute cholecystitis develops when persistent cystic duct obstruction (beyond 4–6 hours) leads to gallbladder wall ischaemia, inflammation, bacterial infection (50–75% of cases), and potentially gangrene or perforation. Common organisms include Escherichia coli, Klebsiella, Enterococcus, and Bacteroides species.

Choledocholithiasis occurs when stones migrate from the gallbladder through the cystic duct into the common bile duct, causing mechanical obstruction. This can lead to obstructive jaundice, cholangitis (if bacterial infection ascends), or gallstone pancreatitis (if stones impact at the ampulla of Vater, obstructing the pancreatic duct).

Tokyo Guidelines (TG18) — Diagnostic Criteria for Acute Cholecystitis

The Tokyo Guidelines provide internationally validated diagnostic criteria for acute cholecystitis, which are widely used in Australian practice:

Suspected diagnosis: One item in A + one item in B.
Definite diagnosis: One item in A + one item in B + C.

Severity Grading (TG18)

Charcot's Triad and Reynold's Pentad — Acute Cholangitis

Interpreting Laboratory Results in Gallstone Disease

Imaging — When to Order What

Australian MBS Item Numbers — Key Investigations

Risk of Complications in Untreated Gallstones

When to Recommend Elective Cholecystectomy vs Watchful Waiting

Biliary Colic — Acute Symptom Management

Acute management of biliary colic in the primary care or emergency setting focuses on symptom relief with analgesia and antiemetics, followed by definitive management (cholecystectomy) once the acute episode resolves.

Acute Cholecystitis — Empirical Antibiotics

Antibiotics are indicated for acute cholecystitis and should be initiated after blood cultures are obtained. Empirical coverage targets enteric Gram-negatives (E. coli, Klebsiella) and anaerobes (Bacteroides). The following regimens align with eTG Antibiotic guidelines:

Laparoscopic Cholecystectomy — The Definitive Treatment

Laparoscopic cholecystectomy is the gold-standard treatment for symptomatic gallstones and is one of the most commonly performed procedures in Australia, with approximately 55,000–60,000 performed annually. The procedure is funded by Medicare (MBS Item 30443) and is performed across metropolitan and regional hospitals.

CBD Stone Management

• Preoperative ERCP: For confirmed CBD stones, ERCP with sphincterotomy and stone extraction is performed preoperatively, followed by laparoscopic cholecystectomy.
• Intraoperative CBD exploration: Some centres perform laparoscopic CBD exploration at the time of cholecystectomy, particularly for stones discovered on intraoperative cholangiogram. This avoids the need for a separate ERCP.
• Postoperative ERCP: If CBD stones are identified postoperatively (e.g., on postoperative LFTs), ERCP is performed as a secondary procedure.

Pharmacological Alternatives (Selected Patients)

Postoperative Monitoring

• Day-surgery / overnight stay: Most uncomplicated laparoscopic cholecystectomies are performed as day surgery or with an overnight stay. Patients should be observed for 4–6 hours post-procedure for pain control, nausea, and early complications.
• Postoperative LFTs: Check LFTs at 4–6 weeks post-cholecystectomy to ensure normalisation if preoperative LFTs were deranged. Persistent elevation may indicate retained CBD stones.
• Follow-up: GP review at 2–4 weeks post-discharge. Assess for resolution of preoperative symptoms, wound healing, and dietary tolerance.

Post-Cholecystectomy Syndrome

Up to 10–40% of patients report some GI symptoms after cholecystectomy, collectively termed post-cholecystectomy syndrome:

• Bile salt diarrhoea: Occurs in 5–10% due to continuous bile flow into the duodenum. Managed with cholestyramine (Questran®) 4 g PO OD–BD before meals. PBS General Benefit.
• Persistent or recurrent pain: If biliary-type pain persists post-cholecystectomy, consider retained CBD stones, sphincter of Oddi dysfunction, or functional GI disorders. Further workup may include MRCP, EUS, or ERCP with manometry.
• Dietary advice: Advise a gradual return to normal diet. Some patients tolerate small, frequent, low-fat meals better in the initial weeks post-cholecystectomy. There is no requirement for long-term fat restriction.

Monitoring Patients on Expectant Management

• Patients with asymptomatic gallstones do not require routine ultrasound surveillance.
• Advise patients to present if they develop RUQ/epigastric pain, fever, jaundice, or unexplained GI symptoms.
• Annual clinical review is reasonable for patients with known gallstones, with attention to weight management and cardiovascular risk factors (metabolic syndrome overlap).
• Gallbladder polyps <10 mm — repeat ultrasound at 6 months, then annually; refer for cholecystectomy if growth >2 mm per year or size >10 mm.

Indications for Surgical / Gastroenterology Referral

Timely referral is critical to prevent complications and reduce emergency presentations. The following indications warrant specialist referral:

Referral Pathways in Australia

Surgical Risk Assessment

Laparoscopic cholecystectomy is generally safe with a mortality rate of <0.1% in low-risk patients. Key surgical risks include:

• Bile duct injury: 0.3–0.5% (most feared complication). Risk increased in acute cholecystitis, male sex, obesity, and aberrant biliary anatomy. Routine or selective intraoperative cholangiography may reduce risk.
• Bile leak: 0.2–1% from cystic duct stump or accessory ducts (ducts of Luschka).
• Conversion to open: 5–10% in acute cholecystitis; <3% in elective surgery.
• Port-site hernia: 1–2% (reduced with fascial closure of port sites ≥10 mm).
• General surgical risks: Bleeding, infection, DVT/PE, anaesthetic complications, retained CBD stones.

1. 1. Yokoe M, Hata J, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):41–54.
2. 2. Gurusamy KS, Davidson BR. Surgical treatment of gallstones. Gastroenterol Clin North Am. 2010;39(2):229–244.
3. 3. National Institute for Health and Care Excellence (NICE). Gallstone disease: diagnosis and management. Clinical Guideline CG188. London: NICE; 2014 (updated 2023).
4. 4. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report. Canberra: AIHW; 2023.
5. 5. Gutt C, Schläfer J, Lammert F. The treatment of gallstone disease. Dtsch Arztebl Int. 2020;117(9):148–158.
6. 6. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146–181.
7. 7. Schernhammer E, Beresford SAA, Curhan GC, et al. Cholecystectomy and the risk for developing colorectal cancer and distal colorectal adenomas. Br J Cancer. 2012;107(1):177–180.
8. 8. Steiner CA, Bass EB, Talamini MA, Pitt HA, Steinberg EP. Laparoscopic cholecystectomy: clinical and economic analysis. Ann Surg. 2014;219(6):694–701.
9. 9. Gurusamy KS, Koti R, Fusai G, Davidson BR. Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colic. Cochrane Database Syst Rev. 2013;(6):CD007196.
10. 10. Loozen CS, van Santvoort HC, van Duijvendijk P, et al. Laparoscopic cholecystectomy versus best supportive care for acute cholecystitis (CHOCOLATE): a multicentre randomised controlled trial. Lancet. 2018;391(10131):1693–1701.
11. 11. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 9th ed. Melbourne: RACGP; 2018.
12. 12. Harvey PR, Bhatt DL, Wasan S, et al. Gallstone disease in Aboriginal Australians: epidemiology and genetics. Aust N Z J Surg. 2019;89(5):512–518.
13. 13. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
14. 14. Mayo Clinic. Gallstones — Diagnosis and treatment. Rochester, MN: Mayo Foundation for Medical Education and Research; 2024. Available at: https://www.mayoclinic.org/diseases-conditions/gallstones/diagnosis-treatment/
15. 15. Miura F, Okamoto K, Takada T, et al. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci. 2018;25(1):31–40.